Loading page…

Report overview

The report presents Formycon's 2023 as a year of strong commercial and development progress, including consolidated revenue of € 77,696K and major milestone payments from the FYB202 partnership. The company advanced regulatory filings and clinical development for its FYB202 and FYB203 biosimilar candidates while continuing to expand its pipeline. It also reported 238 employees and launched its first sustainability strategy with a double-materiality analysis.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language
Pages
File size

Standards & Assurance

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services